III期研究-话题@MedSci

#III期研究#

101篇内容 | 2921人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021381, encodeId=ab012021381ff, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Mirogabalin治疗脊髓损伤后中枢神经性疼痛的III期研究，已取得积极结果, objectType=article, longId=204711, objectId=4bf8204e1113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bf8204e1113, replyNumber=0, likeNumber=68, createdTime=2021-04-07, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bf8204e1113, moduleTitle=Mirogabalin治疗脊髓损伤后中枢神经性疼痛的III期研究，已取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bf8204e1113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021365, encodeId=ccae202136534, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=74, createdTime=2021-04-24, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021366, encodeId=adc52021366cb, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点, objectType=article, longId=196391, objectId=06ff19639198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06ff19639198, replyNumber=0, likeNumber=77, createdTime=2020-06-27, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06ff19639198, moduleTitle=Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06ff19639198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021369, encodeId=bd88202136962, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, objectType=article, longId=197187, objectId=f91619e187c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f91619e187c8, replyNumber=0, likeNumber=71, createdTime=2020-09-07, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f91619e187c8, moduleTitle=抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f91619e187c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021356, encodeId=af84202135643, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, objectType=article, longId=183902, objectId=8908183902b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8908183902b8, replyNumber=0, likeNumber=91, createdTime=2020-02-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8908183902b8, moduleTitle=NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8908183902b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021358, encodeId=d061202135821, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=IMbrave 150：III期研究显示肝癌迎来治愈希望, objectType=article, longId=184473, objectId=124e1844e341, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=124e1844e341, replyNumber=0, likeNumber=89, createdTime=2020-06-16, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=124e1844e341, moduleTitle=IMbrave 150：III期研究显示肝癌迎来治愈希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=124e1844e341)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021368, encodeId=7e9c20213680c, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, objectType=article, longId=197185, objectId=861519e185ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861519e185ee, replyNumber=0, likeNumber=67, createdTime=2021-05-20, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861519e185ee, moduleTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=861519e185ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021355, encodeId=1e1a2021355a8, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生, objectType=article, longId=183120, objectId=cf0b18312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0b18312019, replyNumber=0, likeNumber=54, createdTime=2020-05-29, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0b18312019, moduleTitle=吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0b18312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021362, encodeId=81dd20213626f, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, objectType=article, longId=192565, objectId=2ba3192565fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ba3192565fa, replyNumber=0, likeNumber=61, createdTime=2021-03-19, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ba3192565fa, moduleTitle=Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ba3192565fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021360, encodeId=9bda202136080, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究, objectType=article, longId=185519, objectId=938918551947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=938918551947, replyNumber=0, likeNumber=85, createdTime=2020-10-08, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=938918551947, moduleTitle=三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=938918551947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021350, encodeId=0d30202135074, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, objectType=article, longId=178240, objectId=d4021e824003, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4021e824003, replyNumber=0, likeNumber=72, createdTime=2020-04-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4021e824003, moduleTitle=Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4021e824003)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021357, encodeId=a7b3202135e51, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, objectType=article, longId=184167, objectId=053a18416e94, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=053a18416e94, replyNumber=0, likeNumber=75, createdTime=2020-10-10, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=053a18416e94, moduleTitle=Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=053a18416e94)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021361, encodeId=ae44202136167, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）, objectType=article, longId=191428, objectId=b8ab191428cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ab191428cc, replyNumber=0, likeNumber=88, createdTime=2020-10-28, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ab191428cc, moduleTitle=鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ab191428cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021346, encodeId=e242202134616, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, objectType=article, longId=167609, objectId=9e4316e6096f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e4316e6096f, replyNumber=0, likeNumber=57, createdTime=2019-06-20, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e4316e6096f, moduleTitle=诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e4316e6096f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021364, encodeId=7fd320213648e, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=31, createdTime=2020-09-07, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021348, encodeId=46522021348e7, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=49, createdTime=2020-03-20, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021351, encodeId=c76a202135196, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, objectType=article, longId=178809, objectId=55521e880970, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55521e880970, replyNumber=0, likeNumber=68, createdTime=2020-05-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55521e880970, moduleTitle=Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55521e880970)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021359, encodeId=a3402021359b6, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, objectType=article, longId=185379, objectId=6b761853e9f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b761853e9f9, replyNumber=0, likeNumber=83, createdTime=2020-04-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b761853e9f9, moduleTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b761853e9f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021354, encodeId=a1a02021354f9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, objectType=article, longId=181451, objectId=7dae1814517d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dae1814517d, replyNumber=0, likeNumber=67, createdTime=2019-10-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dae1814517d, moduleTitle=免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7dae1814517d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021347, encodeId=b780202134e13, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, objectType=article, longId=175129, objectId=21e61e5129ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e61e5129ae, replyNumber=0, likeNumber=65, createdTime=2020-03-08, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e61e5129ae, moduleTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e61e5129ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期研究

2020-05-29

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Mirogabalin治疗脊髓损伤后中枢神经性疼痛的III期研究，已取得积极结果

2021-04-07

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2021-04-24

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Relugolix治疗子宫内膜异位症疼痛：III期研究达到所有关键终点

2020-06-27

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

抗体药物偶联物Trodelvy显著改善三阴性乳腺癌患者的PFS：III期研究达到终点

2020-09-07

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

NEJM：Satralizumab治疗视神经脊髓炎谱系疾病的SAkuraSky III期研究取得喜人结果

2020-02-28

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

IMbrave 150：III期研究显示肝癌迎来治愈希望

2020-06-16

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段

2021-05-20

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

吉利德的Vemlidy在III期研究中，可显著降低慢性乙型肝炎感染患者肝细胞癌的发生

2020-05-29

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Incyte启动JAK抑制剂芦可替尼治疗COVID-19相关细胞因子风暴III期研究

2021-03-19

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究

2020-10-08

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

Medicines公司的一年两次PCSK9抑制剂抗动脉粥样硬化达到III期研究的主要目标

2020-04-18

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

Ardelyx的实验性药物Tenapanor达到了高磷血症的第二个III期研究的主要目标

2020-10-10

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

鼻息肉靶向治疗药物研究成功：IL-5单抗mepolizumab的III期研究效果显著（SYNAPSE研究）

2020-10-28

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

诺华IgE单抗Xolair治疗慢性鼻窦炎的两项III期研究达到主要临床终点

2019-06-20

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-09-07

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2020-03-20

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

Ardelyx的钠/氢交换异构体抑制剂tenapanor符合高磷血症的III期研究的主要终点

2020-05-02

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究

2020-04-11

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

免疫疗法pegilodecakin在胰腺癌中的III期研究未能达到总体生存的主要终点

2019-10-26

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性

2020-03-08

科室
- - 订阅+
  - 更多科室
工具
服务